Arrowhead Pharma Reports Executive Compensation Changes
Ticker: ARWR · Form: 8-K · Filed: Jan 22, 2024 · CIK: 879407
Complexity: simple
Sentiment: neutral
Topics: executive-compensation, corporate-governance, 8-K
TL;DR
**Arrowhead Pharma just updated executive pay, watch for strategic shifts.**
AI Summary
Arrowhead Pharmaceuticals, Inc. filed an 8-K on January 22, 2024, reporting an event that occurred on January 16, 2024. This filing indicates a change in compensatory arrangements for certain officers, which could impact the company's financial outlook and executive incentives. Investors should note that changes in executive compensation can signal shifts in company strategy or performance expectations, potentially affecting stock valuation.
Why It Matters
Changes in executive compensation can influence management's motivation and align their interests with shareholders, potentially impacting future company performance and stock value.
Risk Assessment
Risk Level: low — This filing primarily concerns administrative changes related to executive compensation, which typically carries a low direct risk to the company's immediate operations or financial stability.
Analyst Insight
Investors should monitor subsequent filings or company announcements for details regarding the specific changes to compensatory arrangements, as these could provide insights into future executive performance incentives and potential strategic shifts.
Key Players & Entities
- Arrowhead Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- January 16, 2024 (date) — date of the earliest event reported
- January 22, 2024 (date) — date the 8-K was filed
- 001-38042 (other) — Commission File Number
- ARWR (other) — Trading Symbol for Common Stock
- $0.001 (dollar_amount) — par value per share of Common Stock
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 16, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
What specific items are being reported in this 8-K filing by Arrowhead Pharmaceuticals, Inc.?
This 8-K filing reports 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' and 'Financial Statements and Exhibits' under Item Information.
What is the trading symbol and the exchange where Arrowhead Pharmaceuticals, Inc.'s common stock is registered?
The trading symbol for Arrowhead Pharmaceuticals, Inc.'s Common Stock, par value $0.001 per share, is ARWR, and it is registered on The Nasdaq Global Select Market.
What is the address of Arrowhead Pharmaceuticals, Inc.'s principal executive offices?
The address of Arrowhead Pharmaceuticals, Inc.'s principal executive offices is 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105.
What is the par value of Arrowhead Pharmaceuticals, Inc.'s Common Stock?
The par value of Arrowhead Pharmaceuticals, Inc.'s Common Stock is $0.001 per share, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-01-19 18:08:57
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select
Filing Documents
- arwr-20240116.htm (8-K) — 28KB
- 0001628280-24-001805.txt ( ) — 154KB
- arwr-20240116.xsd (EX-101.SCH) — 2KB
- arwr-20240116_lab.xml (EX-101.LAB) — 24KB
- arwr-20240116_pre.xml (EX-101.PRE) — 13KB
- arwr-20240116_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: January 19, 2024 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Kenneth Myszkowski Kenneth Myszkowski Chief Financial Officer